-
Major pharmaceutical firms, including MSD and AstraZeneca, have announced significant cuts to UK investments, citing poor government support, undervaluation of medicines, and an uncompetitive environment. These decisions threaten the UK’s ambitions to be a global life sciences hub, with job losses and stalled projects. The government promises to act, but industry concerns persist.
-
Major pharmaceutical firms have paused or canceled over £2bn in UK investments this year amid concerns over drug pricing policies, US pressure for price parity, and a deteriorating investment climate. Industry warnings highlight risks to future drug development and supply chains.
-
On December 1-2, 2025, WHO issued its first guidelines recommending long-term use of GLP-1 drugs like Wegovy and Mounjaro for obesity treatment, recognizing obesity as a chronic disease. The US government finalized deals lowering prices for these drugs under Medicare and Medicaid, expanding coverage to more patients. Despite benefits, studies show weight and health gains reverse if treatment stops, highlighting need for ongoing care.